Trial · NCT01028911
Outcomes32
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 32
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinically Significant Vital Sign Abnormalities | Baseline up to 7 to 10 days after last dose | Safety population included all participants who took at least 1 dose of study drug. | participants | NUMBER |
| PRIMARY | Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | Baseline up to 7 to 10 days after last dose | Safety population included all participants who took at least 1 dose of study drug. | participants | NUMBER |
| PRIMARY | Number of Participants With Clinically Significant Laboratory Test Abnormalities | Baseline up to 7 to 10 days after last dose | Safety population included all participants who took at least 1 dose of study drug. | participants | NUMBER |
| PRIMARY | Number of Participants With Clinically Significant Change From Baseline in Physical Examination | Baseline up to 7 to 10 days after last dose | Safety population included all participants who took at least 1 dose of study drug. | participants | NUMBER |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Baseline | Baseline | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 5 | Day 5 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 10 | Day 10 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 15 | Day 15 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 20 | Day 20 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 25 | Day 25 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Day 30 | Day 30 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Medical Outcomes Study - Sleep Scale (MOS-SS) Score at Follow-up | Follow-up (7 to 10 days after last dose) | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 5 | Baseline, Day 5 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 10 | Baseline, Day 10 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 15 | Baseline, Day 15 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 20 | Baseline, Day 20 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 25 | Baseline, Day 25 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Day 30 | Baseline, Day 30 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Follow-up | Baseline, Follow-up (7 to 10 days after last dose) | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Day 5 | Baseline, Day 5 | Safety population included all participants who took at least 1 dose of study drug. | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01028911/outcomes